|Bid||40.15 x 900|
|Ask||40.19 x 1200|
|Day's Range||38.53 - 40.68|
|52 Week Range||34.11 - 55.12|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||45.75|
Adaptive Biotechnologies Corporation (ADPT) today announced it has entered into a global agreement with Amgen for the use of Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MRD) across multiple drug development programs within the Amgen hematology portfolio.
Shares of Adaptive Biotechnologies Corp. fell 8.5% in premarket trade Wednesday after the company reported earnings that fell short of analysts' expectations and predicted lower-than-expected full-year revenue. Adaptive, which went public in June, reported late Tuesday a second-quarter loss of $16.4 million, or $1.23 a share, after a loss of $12.5 million, or $1.01 a share, in the year-earlier quarter. FactSet analysts had expected a loss of 14 cents a share. Revenue grew to $22.1 million from $11.6 million in the year-ago quarter, topping the FactSet consensus of $19.4 million. Adaptive said it was expecting 2019 revenue of between $78 million and $81 million. That was below the $81.9 million that analysts polled by FactSet had predicted. Shares of Adaptive have gained 115% since the company priced its IPO in June at $20 a share.
Adaptive Biotechnologies Corp. shares were down fractionally in the extended session Tuesday after the biotech company reported a narrower-than-expected loss. Adaptive Biotech shares declined 0.1% after hours, following a 2.6% rise in the regular session to close at $43.08. The company reported second-quarter loss of $16.4 million, or $1.23 a share, compared with a loss of $12.5 million, or $1.01 a share, in the year-ago period. The adjusted loss was $10.9 million. Revenue rose to $22.1 million from $11.6 million in the year-ago quarter. Analysts surveyed by FactSet had forecast a loss of $17.7 million on revenue of $19.4 million. The report was the company's first since going public in July. Shares have gained 115% since the company priced its IPO at $20 a share.
SEATTLE, Aug. 13, 2019 -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today reported financial results for the quarter ended June 30, 2019..
(Bloomberg) -- Shares in three of the year’s hottest IPOs, Uber Technologies Inc., Revolve Group Inc. and Fastly Inc., plunged Friday as the latest batch of newly listed companies reported some of the most disappointing results this earnings season.Uber shares ended Friday 6.8% lower after the ride-hailing company missed sales estimates. Revolve fell 15.6% after the fashion e-tailer reported earnings below expectations. And Fastly, which saw its shares dip below its IPO price intraday, declined 18.1% after reporting lighter than expected margins.The disappointment spread to other IPOs that have not even reported yet, with RealReal Inc. shares tumbling 23% to below its IPO price of $20.Call it an upset, given the hype that tends to follow IPOs. Among the nearly 20 freshly listed companies that reported earnings this week, the majority fell in the next session. IPOs are rising 0.2% on average following reports, lagging behind S&P 500 stocks, which climbed 5.3% on average, according to data compiled by Bloomberg.Other newcomers on deck to report earnings include Adaptive Biotechnologies Corp., Greenlane Holdings Inc., RealReal Inc., and Grocery Outlet Holding Inc. They are among the more well-received IPOs of this year with stocks that opened at least 40% above their offer prices. All are first-time reporters.Cross-border IPOs will be tested as well when China’s big brands So-Young International Inc. and Luckin Coffee Inc. do their show-and-tell.(Updates shares in 1st and 2nd paragraphs, adds RealReal shares in 3rd.)\--With assistance from Drew Singer.To contact the reporter on this story: Crystal Kim in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Brad Olesen at email@example.com, Jennifer Bissell-Linsk, Richard RichtmyerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Adaptive Biotechnologies announced Wednesday that it signed a lease for its headquarters to be located in the heart of Lake Union's life science cluster.
SEATTLE, Aug. 07, 2019 -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial-stage biotechnology company that reads and translates the genetic code of the.
Adaptive Biotechnologies (ADPT) today announced that it will report financial results for the second quarter of 2019 after market close on Tuesday, August 13, 2019. Investors interested in listening to the conference call may do so by dialing (800) 361-2311 for U.S. callers or (409) 937-8761 for international callers (Conference ID: 3095467). Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.
Adaptive Biotechnologies Corporation (ADPT) (“Adaptive”), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system with the goal of developing personalized diagnostics and therapeutics to improve patient lives, today announced that the State of New York Clinical Laboratory Evaluation Program (CLEP) has approved the clonoSEQ® Assay for the detection and monitoring of minimal residual disease (MRD) in patients with B-cell blood cancers.
Microsoft (MSFT) has unveiled its next-generation video game console in the midst of contemplating Xbox production cuts in China.
Adaptive Biotechnologies Corporation (ADPT) (“Adaptive”), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system to develop personalized diagnostics and therapeutics to improve patient lives, today announced the closing of its initial public offering of 15,000,000 shares of common stock, and the exercise in full of the underwriters’ option to purchase 2,250,000 additional shares of its common stock, at a public offering price of $20.00 per share. Goldman Sachs & Co. LLC, J.P. Morgan and BofA Merrill Lynch acted as joint lead book-running managers for the offering.
MarketWatch spoke with Adaptive Biotechnologies’ Chief Executive Chad Robins about the IPO, what’s next for the company and what it’s like working with his older brother.
the Seattle company seeking to use the genetics of the immune system in life-sciences research and drug development, doubled on Thursday, their first day of trading. On Wednesday Adaptive priced an IPO of 15 million shares at $20, exceeding the estimated range of $18 to $19 a share and an earlier estimate of $15 to $17. The underwriters have a 30-day option on 2.25 million more shares at the IPO price.
Shares of Adaptive Biotechnologies Corp. rocketed in their public debut Thursday, as investors flocked to the life-sciences research company that’s looking to the immune system to cure the world’s ills. The $18-to$19 estimate was already a boost from the company’s original pricing range of between $15 and $17 a share. Adaptive, a life-sciences research and clinical diagnostics company, believes data from the immune system is the key to diagnosing and treating diseases.
Adaptive Biotechnologies Corp. shares rocketed 96% in their first ten minutes of trade Thursday, after the company priced its initial public offering above its price range. The life-sciences research and clinical diagnostics company that says data from the immune system is the key to diagnosing and treating diseases, priced its IPO at $20 a share, bove the pricing range it gave early Wednesday of between $18 and $19, which was already a boost from the company's original pricing range of between $15 and $17 a share. Adaptive sold 15 million shares to raise $300 million, and shares are trading on the Nasdaq under the symbol ADPT. The stock of BridgeBio Pharma Inc. , meanwhile, soared more than 70% in its trading debut. That company also priced its IPO above the price range, selling 20.5 million shares priced at $17 each to raise $348.6 million. The price range was $14 to $16. The stock is trading on Nasdaq, under the ticker symbol "BBIO."
The IPO market is heating up as the healthcare and biotech sectors take center stage. Yahoo Finance's Zack Guzman & Kristin Myers discuss with New Constructs Investment Analyst Sam McBride.
Adaptive Biotechnologies increased the number of shares it will sell in its initial public offering. Yahoo Finance's Ines Ferre has the story.